vs
Mama's Creations, Inc.（MAMA）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Mama's Creations, Inc.的季度营收约是REGENXBIO Inc.的1.6倍（$47.3M vs $30.3M），Mama's Creations, Inc.净利率更高（1.1% vs -221.3%，领先222.5%），Mama's Creations, Inc.同比增速更快（50.0% vs 43.0%），Mama's Creations, Inc.自由现金流更多（$3.7M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 33.0%）
Mama's Creations是一家美国食品制造企业，主要生产冷藏即食、加热即食类食品，涵盖意式肉丸、香肠、意面餐食等预制菜品，产品主要供应美国本土的零售商超、大众零售商及餐饮服务合作伙伴，主打便捷高品质的家常风味食品。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
MAMA vs RGNX — 直观对比
营收规模更大
MAMA
是对方的1.6倍
$30.3M
营收增速更快
MAMA
高出6.9%
43.0%
净利率更高
MAMA
高出222.5%
-221.3%
自由现金流更多
MAMA
多$56.5M
$-52.8M
两年增速更快
RGNX
近两年复合增速
33.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $47.3M | $30.3M |
| 净利润 | $540.0K | $-67.1M |
| 毛利率 | 23.6% | — |
| 营业利润率 | 1.7% | -190.0% |
| 净利率 | 1.1% | -221.3% |
| 营收同比 | 50.0% | 43.0% |
| 净利润同比 | 31.7% | -31.2% |
| 每股收益（稀释后） | $0.01 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MAMARGNX
| Q4 25 | $47.3M | $30.3M | ||
| Q3 25 | $35.2M | $29.7M | ||
| Q2 25 | $35.3M | $21.4M | ||
| Q1 25 | $33.6M | $89.0M | ||
| Q4 24 | $31.5M | $21.2M | ||
| Q3 24 | $28.4M | $24.2M | ||
| Q2 24 | $29.8M | $22.3M | ||
| Q1 24 | $26.7M | $15.6M |
净利润MAMARGNX
| Q4 25 | $540.0K | $-67.1M | ||
| Q3 25 | $1.3M | $-61.9M | ||
| Q2 25 | $1.2M | $-70.9M | ||
| Q1 25 | $1.6M | $6.1M | ||
| Q4 24 | $410.0K | $-51.2M | ||
| Q3 24 | $1.1M | $-59.6M | ||
| Q2 24 | $553.0K | $-53.0M | ||
| Q1 24 | $1.4M | $-63.3M |
毛利率MAMARGNX
| Q4 25 | 23.6% | — | ||
| Q3 25 | 24.9% | — | ||
| Q2 25 | 26.1% | — | ||
| Q1 25 | 27.0% | — | ||
| Q4 24 | 22.6% | 70.2% | ||
| Q3 24 | 24.2% | 48.8% | ||
| Q2 24 | 25.0% | 52.5% | ||
| Q1 24 | 29.3% | 72.6% |
营业利润率MAMARGNX
| Q4 25 | 1.7% | -190.0% | ||
| Q3 25 | 4.8% | -176.3% | ||
| Q2 25 | 4.5% | -296.3% | ||
| Q1 25 | 5.7% | 13.6% | ||
| Q4 24 | 1.8% | -242.1% | ||
| Q3 24 | 5.7% | -256.6% | ||
| Q2 24 | 2.6% | -251.3% | ||
| Q1 24 | 7.4% | -408.8% |
净利率MAMARGNX
| Q4 25 | 1.1% | -221.3% | ||
| Q3 25 | 3.6% | -208.3% | ||
| Q2 25 | 3.5% | -331.8% | ||
| Q1 25 | 4.8% | 6.8% | ||
| Q4 24 | 1.3% | -241.3% | ||
| Q3 24 | 4.0% | -246.3% | ||
| Q2 24 | 1.9% | -237.7% | ||
| Q1 24 | 5.3% | -405.4% |
每股收益（稀释后）MAMARGNX
| Q4 25 | $0.01 | $-1.30 | ||
| Q3 25 | $0.03 | $-1.20 | ||
| Q2 25 | $0.03 | $-1.38 | ||
| Q1 25 | $0.04 | $0.12 | ||
| Q4 24 | $0.01 | $-0.99 | ||
| Q3 24 | $0.03 | $-1.17 | ||
| Q2 24 | $0.01 | $-1.05 | ||
| Q1 24 | $0.03 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $49.6M | $102.7M |
| 总资产 | $84.0M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MAMARGNX
| Q4 25 | $18.1M | $230.1M | ||
| Q3 25 | $9.4M | $274.2M | ||
| Q2 25 | $12.0M | $323.3M | ||
| Q1 25 | $7.2M | $267.9M | ||
| Q4 24 | $9.3M | $234.7M | ||
| Q3 24 | $7.4M | $255.5M | ||
| Q2 24 | $13.0M | $290.4M | ||
| Q1 24 | $11.0M | $338.7M |
股东权益MAMARGNX
| Q4 25 | $49.6M | $102.7M | ||
| Q3 25 | $29.6M | $161.5M | ||
| Q2 25 | $26.4M | $213.7M | ||
| Q1 25 | $24.9M | $274.2M | ||
| Q4 24 | $23.0M | $259.7M | ||
| Q3 24 | $22.3M | $301.4M | ||
| Q2 24 | $20.3M | $348.3M | ||
| Q1 24 | $19.6M | $390.7M |
总资产MAMARGNX
| Q4 25 | $84.0M | $453.0M | ||
| Q3 25 | $51.2M | $525.2M | ||
| Q2 25 | $52.7M | $581.0M | ||
| Q1 25 | $47.1M | $490.9M | ||
| Q4 24 | $47.9M | $466.0M | ||
| Q3 24 | $43.0M | $519.1M | ||
| Q2 24 | $47.2M | $569.4M | ||
| Q1 24 | $45.1M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $3.7M | $-52.8M |
| 自由现金流率自由现金流/营收 | 7.8% | -174.0% |
| 资本支出强度资本支出/营收 | 0.4% | 1.7% |
| 现金转化率经营现金流/净利润 | 7.16× | — |
| 过去12个月自由现金流最近4个季度 | $6.0M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流MAMARGNX
| Q4 25 | $3.9M | $-52.3M | ||
| Q3 25 | $-1.7M | $-56.0M | ||
| Q2 25 | $6.0M | $-49.3M | ||
| Q1 25 | $-857.0K | $33.6M | ||
| Q4 24 | $4.8M | $-31.6M | ||
| Q3 24 | $-2.4M | $-40.5M | ||
| Q2 24 | $3.6M | $-45.5M | ||
| Q1 24 | $6.7M | $-55.5M |
自由现金流MAMARGNX
| Q4 25 | $3.7M | $-52.8M | ||
| Q3 25 | $-2.2M | $-56.5M | ||
| Q2 25 | $5.5M | $-49.7M | ||
| Q1 25 | $-930.0K | $32.6M | ||
| Q4 24 | $2.5M | $-32.7M | ||
| Q3 24 | $-4.0M | $-40.9M | ||
| Q2 24 | $2.5M | $-46.0M | ||
| Q1 24 | $6.6M | $-56.0M |
自由现金流率MAMARGNX
| Q4 25 | 7.8% | -174.0% | ||
| Q3 25 | -6.2% | -189.9% | ||
| Q2 25 | 15.5% | -232.8% | ||
| Q1 25 | -2.8% | 36.6% | ||
| Q4 24 | 8.0% | -154.2% | ||
| Q3 24 | -14.1% | -168.9% | ||
| Q2 24 | 8.4% | -206.2% | ||
| Q1 24 | 24.8% | -358.5% |
资本支出强度MAMARGNX
| Q4 25 | 0.4% | 1.7% | ||
| Q3 25 | 1.5% | 1.7% | ||
| Q2 25 | 1.5% | 1.8% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | 7.2% | 5.1% | ||
| Q3 24 | 5.6% | 1.3% | ||
| Q2 24 | 3.8% | 2.1% | ||
| Q1 24 | 0.4% | 3.6% |
现金转化率MAMARGNX
| Q4 25 | 7.16× | — | ||
| Q3 25 | -1.31× | — | ||
| Q2 25 | 4.85× | — | ||
| Q1 25 | -0.54× | 5.53× | ||
| Q4 24 | 11.71× | — | ||
| Q3 24 | -2.10× | — | ||
| Q2 24 | 6.58× | — | ||
| Q1 24 | 4.79× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAMA
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
